PVG Asset Management Corp Takes $48,000 Position in Vanda Pharmaceuticals Inc. $VNDA

PVG Asset Management Corp bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,375 shares of the biopharmaceutical company’s stock, valued at approximately $48,000.

Other institutional investors have also modified their holdings of the company. Two Sigma Investments LP raised its stake in shares of Vanda Pharmaceuticals by 94.7% in the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 97,017 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 121,797 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $2,022,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $875,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $240,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ:VNDA opened at $4.60 on Friday. The firm’s 50 day moving average is $4.61 and its two-hundred day moving average is $4.54. Vanda Pharmaceuticals Inc. has a 52 week low of $3.81 and a 52 week high of $5.55. The firm has a market capitalization of $271.81 million, a P/E ratio of -4.07 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%.The company had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on VNDA. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and a consensus price target of $16.50.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.